HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use XALATAN safely and effectively. See full prescribing information for XALATAN.
XALATAN® (latanoprost ophthalmic solution) 0.005%, for topical ophthalmic use
Initial U.S. Approval: 1996
INDICATIONS AND USAGE
XALATAN is a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. (1)
DOSAGE AND ADMINISTRATION
One drop in the affected eye(s) once daily in the evening. (2)
DOSAGE FORMS AND STRENGTHS
Ophthalmic solution containing latanoprost 50 mcg/mL (0.005%). (3)
Known hypersensitivity to latanoprost, benzalkonium chloride or any other ingredients in this product. (4)
WARNINGS AND PRECAUTIONS
Most common adverse reactions (5–15%) from clinical trials are blurred vision, burning and stinging, conjunctival hyperemia, foreign body sensation, itching, increased pigmentation of the iris, and punctate keratitis. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See 17 for PATIENT COUNSELING INFORMATION.
No Current Announcements.
Contact Pfizer Medical
Report an Adverse Event